Combination Therapy Plus Fluvastatin Improves Hep C Outcome
Whether or not a person has metabolic syndrome, new research shows that adding fluvastatin to standard Hepatitis C combination therapy improves response rates.
Continue reading »Hepatitis C Treatments/Therapies
Hepatitis C Hopeful PPI-461 Getting Good Marks in Phase 1b Trial
Interim safety and efficacy data on Presidio's NS5A inhibitor, PPI-461, indicates that this novel drug could be a top Hepatitis C therapy contender.
Continue reading »Next Stage for Biotron's Hep C Drug
Australian biotech company, Biotron, concluded the first part of its Phase 2 trial evaluating BIT225, its Hepatitis C drug contender.
Continue reading »Telaprevir Shows Promise in Those Co-Infected with Hepatitis C and HIV
Mar 15, 2011
2 Comments
Preliminary results from a Phase 2 trial demonstrated that 70 percent of people co-infected with Hepatitis C and HIV had undetectable levels of Hepatitis C after just four weeks of treatment with telaprevir.
Continue reading »Interferon-Free Combo Squashes the Hepatitis C Virus
Mar 15, 2011
4 Comments
New data about a combination of Pharmasset's developmental drugs claim a 94 percent success rate for Hepatitis C in just two weeks. Not only were these drugs highly effective in a short period of time, but they also did so without interferon.
Continue reading »Strides Made Towards Hepatitis C Preventative Vaccine
By utilizing a cold virus molecule, Danish researchers may have found a way to inoculate people against Hepatitis C.
Continue reading »Human Trials to Begin on Hepatitis C Drug
After encouraging pre-clinical studies, Medivir and Tibotec are beginning a Phase 1a trial of their Hepatitis C nucleoside inhibitor.
Continue reading »Immune Activation Repurposed for Developing Hepatitis C Therapy
Medical chemists from the UK are working on an oral Hepatitis C drug that works by activating a protein in the immune system.
Continue reading »Inhibitex's Hep C Drug Gets Fast-Tracked
As a result of the need for improved treatments, the FDA granted fast track development to INX-08189, a guanosine nucleotide polymerase inhibitor for treating Hepatitis C.
Continue reading »Telaprevir Receives Quick FDA Review
Likely due to its ability to dramatically improve the Hepatitis C cure rate, Vertex's telaprevir will get a priority review by the FDA.
Continue reading »
